Von Hippel-Lindau Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the group of the VHL tumors the SDHB somatic events were significantly lower (2/6; p=0.045).
|
22573489 |
2012 |
Von Hippel-Lindau Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There were 2 cases of false-negative results each in the group with SDHB (2/12) and VHL mutations (2/19) and 1 false-negative result in the subgroup of patients with unknown mutation status (1/6).
|
22836345 |
2012 |
Von Hippel-Lindau Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the von Hippel-Lindau disease (VHL) and succinate dehydrogenase subunit B (SDHB) genes can cause inherited phaeochromocytoma and/or renal cell carcinoma (RCC).
|
20959442 |
2011 |
Von Hippel-Lindau Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The paraganglioma-pheochromocytoma syndrome is caused by germline-inactivating mutations in the mitochondrial succinate dehydrogenase (SDH) genes SDHB, SDHC, SDHD, or SDHAF2, and VHL is the result of inactivating VHL gene mutations.
|
19915015 |
2010 |
Von Hippel-Lindau Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression data from 67 HIF target genes was sufficient to cluster SDHB and VHL tumors into two different groups, demonstrating different pseudo-hypoxic signatures.
|
20980436 |
2010 |
Von Hippel-Lindau Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with PGL 4 and less frequently VHL, are particularly predisposed to malignant pheochromocytoma.
|
19269919 |
2009 |
Von Hippel-Lindau Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Seven patients with a sporadic or syndromic EAP (n = 4: von Hippel-Lindau syndrome and SDHB, SDHC, and SDHD gene mutations) underwent reoperation for a local-regional recurrence after a median time of 46 months (interquartile range [IQR], 16-100).
|
19958924 |
2009 |
Von Hippel-Lindau Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In 166 patients (25.9%) the disease was familial and caused by germline mutations in VHL (56), SDHB (34), SDHD (31), RET (31) or NF1 (14), causing von Hippel-Lindau disease, SDHB- or SDHD-PH/FPGL syndromes, multiple endocrine neoplasia type 2 (MEN 2) and type 1 neurofibromatosis (NF1), respectively.
|
17121518 |
2006 |
Von Hippel-Lindau Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutation screening of genes associated to VHL (VHL), MEN (RET), and familial PGL (SDH-B, -C, and -D) showed that all cases had germline deletions in the SDHB gene.
|
16304664 |
2006 |
Von Hippel-Lindau Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Germline SDHB and SDHD mutations also lead to increased expression of HIF target genes, but it appears that phaeochromocytoma susceptibility in VHL disease cannot be attributed to HIF activation alone.
|
16728571 |
2006 |
Von Hippel-Lindau Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phaeochromocytoma is a neural-crest-derived tumour that may be a feature of several familial cancer syndromes including von Hippel-Lindau (VHL) disease, multiple endocrine neoplasia type 2 (MEN 2), neurofibromatosis type 1 (NF1) and germline succinate dehydrogenase subunit (SDHB and SDHD) mutations.
|
15788647 |
2005 |
Von Hippel-Lindau Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, our increased understanding of the three hereditary syndromes (neurofibromatosis 1, multiple endocrine neoplasia type 2, and von Hippel-Lindau syndrome) in which pheochromocytoma is found and the recent discovery that mutations in genes in the succinate dehydrogenase family (SDHB and SDHD) predispose to pheochromocytoma have necessitated a re-evaluation of the genetic basis of pheochromocytoma.
|
12928344 |
2003 |
Von Hippel-Lindau Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
About 10% of the patients with pheochromocytomas and paragangliomas present with a family history of von Hippel-Lindau disease (VHL), Multiple endocrine neoplasia type 2 (MEN2), one of the three familial paraganglioma syndromes (PGL; PGL1, PGL3, PGL4), or neurofibromatosis type 1 (NF1).
|
14739490 |
2003 |